Monte Rosa Therapeutics, Inc. Defined Benefit Plan, Interest Cost
Monte Rosa Therapeutics, Inc. (GLUE) reported Defined Benefit Plan, Interest Cost of $9.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedBenefitPlanInterestCost · last filed 2022-03-29
- Monte Rosa Therapeutics, Inc. defined benefit plan, interest cost for fiscal 2021 was $9.00K.
- Monte Rosa Therapeutics, Inc. defined benefit plan, interest cost for fiscal 2020 was $0.00.
| Period end | Defined Benefit Plan, Interest Cost 12 month |
|---|---|
| 2021-12-31 | $9.00K 10-K · filed 2022-03-29 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |